Personalis Inc (PSNL)

$9.89 +0.28 (2.91%)
Market Cap 825.88M
Revenue (ttm) 84.61M
Net Income (ttm) -81.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.06%
Debt to Equity Ratio 0.00
Volume 3,107,600
Avg Vol 1,535,842
Day's Range N/A - N/A
Shares Out 88.80M
Stochastic %K 90%
Beta 1.96
Analysts Strong Sell
Price Target $11.00

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 752 1300
Fax: 650 752 1301
Address:
6600 Dumbarton Circle, Fremont, United States
lucianw
lucianw Jan. 16 at 9:04 PM
$PSNL dumped before close like clockwork
1 · Reply
Penki1985
Penki1985 Jan. 16 at 7:37 PM
$PSNL Can we get 12 until ER?
1 · Reply
Wax_Bean_futures
Wax_Bean_futures Jan. 16 at 6:23 PM
$PSNL Go....Go....GO!!!
0 · Reply
MD109
MD109 Jan. 16 at 5:44 PM
$PSNL Hold tight. As I’ve said before, Personalis/Tempus will become a leader in a space that is just starting to get fully appreciated by large institutional investors. Barely scratching the surface in terms of MRD usage by clinicians and pharma/biotech. Their assay performance, balance sheet, near future margin expansion, imminent Medicare coverage approvals and go to market strategy are all reasons to be very bullish on the trajectory of this great company.
0 · Reply
Skibum77
Skibum77 Jan. 16 at 5:31 PM
$PSNL that was quite a print somebody jumped in with both feet
1 · Reply
BioTechNoir
BioTechNoir Jan. 16 at 5:30 PM
$PSNL its our year baby
1 · Reply
BeeDecay
BeeDecay Jan. 16 at 5:25 PM
$PSNL That was a 2,000,000 share block right at $10.00.
1 · Reply
Universaal
Universaal Jan. 16 at 5:24 PM
$PSNL turning into 20% day
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 16 at 5:20 PM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: FEB 20 2026 Buy in Price: $1.00 - $1.05 Sell Price: $1.67 Profit : +67% (Turn every $1 into $1.67) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Universaal
Universaal Jan. 16 at 5:12 PM
$PSNL 2.5 million volume someone loading
0 · Reply
Latest News on PSNL
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Jan 12, 2026, 4:00 PM EST - 4 days ago

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Jan 8, 2026, 8:00 AM EST - 8 days ago

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Dec 17, 2025, 6:00 AM EST - 4 weeks ago

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Dec 11, 2025, 9:00 AM EST - 5 weeks ago

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 4:01 PM EST - 2 months ago

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 10, 2025, 9:00 AM EST - 2 months ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:46 PM EST - 2 months ago

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Personalis Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 2 months ago

Personalis Reports Third Quarter 2025 Financial Results

Personalis to Announce Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 3 months ago

Personalis to Announce Third Quarter 2025 Financial Results

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Oct 16, 2025, 9:00 AM EDT - 3 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 15, 2025, 5:35 PM EDT - 4 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 10, 2025, 4:05 PM EDT - 4 months ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Sep 3, 2025, 4:05 PM EDT - 4 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Personalis to Participate in Upcoming Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 5 months ago

Personalis to Participate in Upcoming Investor Conferences

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Aug 6, 2025, 8:11 AM EDT - 5 months ago

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

SMCI

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:49 PM EDT - 5 months ago

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Personalis Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:01 PM EDT - 5 months ago

Personalis Reports Second Quarter 2025 Financial Results

Personalis to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 6 months ago

Personalis to Announce Second Quarter 2025 Financial Results

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Jul 9, 2025, 4:00 PM EDT - 6 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 3, 2025, 4:00 PM EDT - 8 months ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Jun 2, 2025, 4:00 PM EDT - 8 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 22, 2025, 6:00 AM EDT - 8 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 14, 2025, 4:01 PM EDT - 8 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 8:41 PM EDT - 9 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

Personalis Reports First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 9 months ago

Personalis Reports First Quarter 2025 Financial Results

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 28, 2025, 5:00 PM EDT - 9 months ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 4:01 PM EDT - 9 months ago

Personalis to Announce First Quarter 2025 Financial Results

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Apr 22, 2025, 6:00 AM EDT - 9 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 4:01 PM EDT - 10 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Mar 3, 2025, 6:00 AM EST - 11 months ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:40 PM EST - 11 months ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:01 PM EST - 11 months ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 11 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 18, 2025, 4:01 PM EST - 11 months ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 14, 2025, 10:50 AM EST - 1 year ago

Exciting Technology At Personalis, But Profitability Eludes Them

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:01 PM EST - 1 year ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 13, 2025, 5:00 AM EST - 1 year ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Jan 7, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 19, 2024, 9:00 AM EST - 1 year ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Personalis and Tempus Expand Collaboration to Biopharma

Dec 16, 2024, 8:00 AM EST - 1 year ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Personalis to Participate at Upcoming Investor Conferences

Nov 20, 2024, 4:01 PM EST - 1 year ago

Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:11 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Personalis Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:01 PM EST - 1 year ago

Personalis Reports Third Quarter 2024 Financial Results

Personalis to Present at the Stifel 2024 Healthcare Conference

Nov 5, 2024, 4:01 PM EST - 1 year ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Personalis to Announce Third Quarter 2024 Financial Results

Oct 23, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Third Quarter 2024 Financial Results

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Sep 16, 2024, 9:00 AM EDT - 1 year ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Personalis: Resetting My Strategy Following The Q2 Beat

Aug 18, 2024, 7:47 AM EDT - 1 year ago

Personalis: Resetting My Strategy Following The Q2 Beat

Personalis and Tempus Announce Expanded Collaboration

Aug 16, 2024, 8:30 AM EDT - 1 year ago

Personalis and Tempus Announce Expanded Collaboration

TEM

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 11:09 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

lucianw
lucianw Jan. 16 at 9:04 PM
$PSNL dumped before close like clockwork
1 · Reply
Penki1985
Penki1985 Jan. 16 at 7:37 PM
$PSNL Can we get 12 until ER?
1 · Reply
Wax_Bean_futures
Wax_Bean_futures Jan. 16 at 6:23 PM
$PSNL Go....Go....GO!!!
0 · Reply
MD109
MD109 Jan. 16 at 5:44 PM
$PSNL Hold tight. As I’ve said before, Personalis/Tempus will become a leader in a space that is just starting to get fully appreciated by large institutional investors. Barely scratching the surface in terms of MRD usage by clinicians and pharma/biotech. Their assay performance, balance sheet, near future margin expansion, imminent Medicare coverage approvals and go to market strategy are all reasons to be very bullish on the trajectory of this great company.
0 · Reply
Skibum77
Skibum77 Jan. 16 at 5:31 PM
$PSNL that was quite a print somebody jumped in with both feet
1 · Reply
BioTechNoir
BioTechNoir Jan. 16 at 5:30 PM
$PSNL its our year baby
1 · Reply
BeeDecay
BeeDecay Jan. 16 at 5:25 PM
$PSNL That was a 2,000,000 share block right at $10.00.
1 · Reply
Universaal
Universaal Jan. 16 at 5:24 PM
$PSNL turning into 20% day
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 16 at 5:20 PM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: FEB 20 2026 Buy in Price: $1.00 - $1.05 Sell Price: $1.67 Profit : +67% (Turn every $1 into $1.67) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Universaal
Universaal Jan. 16 at 5:12 PM
$PSNL 2.5 million volume someone loading
0 · Reply
GGator
GGator Jan. 16 at 4:27 PM
$PSNL I’m not going to mention anything this time about single or double digits…
0 · Reply
Skibum77
Skibum77 Jan. 16 at 3:33 PM
$PSNL frisky today
0 · Reply
Trader_Ty
Trader_Ty Jan. 16 at 3:26 PM
$PSNL 1:1 will be sold today
0 · Reply
Trader_Ty
Trader_Ty Jan. 16 at 3:07 PM
$PSNL
0 · Reply
MaximillionJewell
MaximillionJewell Jan. 16 at 3:32 AM
$PSNL 🧐
1 · Reply
Skibum77
Skibum77 Jan. 15 at 8:18 PM
$PSNL hmmmm
4 · Reply
JFais
JFais Jan. 15 at 3:01 PM
$PSNL- adding to my DD list as well (first glance seems like a critical year for them) Coverage improving, reimbursement pending, AI partnership generating increased volume (caveat on margin compression)
1 · Reply
RockyMontana
RockyMontana Jan. 15 at 2:57 PM
$PSNL added
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 11:54 PM
Enter: $PSNL Calls Strike Price: $10 Expiry Date: FEB 20 2026 Buy in Price: $0.80 - $2.75 Sell Price: $1.54 Profit : +93% (Turn every $1 into $1.93) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
magnitudeFC
magnitudeFC Jan. 14 at 9:20 PM
$PSNL Has the transcript of what they said at the J P Morgan conference been posted anywhere?
1 · Reply
BioTechNoir
BioTechNoir Jan. 14 at 8:58 PM
$PSNL STROMG LIKE BULL
0 · Reply
Trader_Ty
Trader_Ty Jan. 14 at 6:58 PM
$PSNL monthly
0 · Reply